The potential of galectin-specific siRNA in increasing the survival of mice with glioma has been shown by Danhier and colleagues using a combination of EGFR and Gal-1-specific siRNA combined with TMZ using chitosan lipid nanocapsules that were injected intracranially [135]. This evidence concerns the gene GAL and central nervous system cancer.